Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Section snippets
Somatostatin Receptor–Based Radionuclide Therapy
Gastroenteropancreatic neuroendocrine tumors (GEPNETs), which comprise functioning and nonfunctioning endocrine pancreatic tumors and carcinoids, are usually slow-growing. When metastasized, treatment with somatostatin analogues results in reduced hormonal overproduction and symptomatic relief in most cases. Treatment with somatostatin analogues is however seldom successful in terms of tumor size reduction.2, 3, 4
A new treatment modality for patients with inoperable or metastasized endocrine
Conclusions
Treatment with radiolabeled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In, 90Y, or 177Lu-labeled somatostatin analogues that have been used for PRRT. The results that were obtained with [90Y-DOTA0, Tyr3]octreotide and [177Lu-DOTA0, Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of
References (68)
- et al.
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Am J Gastroenterol
(2000) - et al.
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The Rotterdam experience
Semin Nucl Med
(2002) - et al.
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Semin Nucl Med
(2002) - et al.
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
Ann Oncol
(2001) - et al.
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors
Semin Nucl Med
(2006) - et al.
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology group
Semin Nucl Med
(2002) - et al.
111In- and 90Y-DOTA-Lanreotide: Results and implications of the Mauritius trial
Semin Nucl Med
(2002) - et al.
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Ann Oncol
(1997) - et al.
Epidemiology and survival in patients with carcinoid disease in the NetherlandsAn epidemiological study with 2391 patients
Ann Oncol
(2001) - et al.
Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival
Surgery
(2007)